Name : Human CD160 Protein
Product Source :
Recombinant Human CD160 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Gly25-Leu158.[Accession | O95971]
Molecular Weight :
The protein has a predicted MW of 17.7 kDa. Due to glycosylation, the protein migrates to 27-33 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human CD160 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Human CD160 is greater than 95% as determined by SEC-HPLC. SPR Data Human HVEM, hFc Tag captured on CM5 Chip via Protein A can bind Human CD160, His Tag with an affinity constant of 1.44 μM as determined in SPR assay (Biacore T200).
Background :
CD160 (also Natural killer cell receptor BY55) is a 27 ‑ 30 kDa member of the Ig superfamily. In human, it is expressed principally on nonmyeloid hematopoietic cells. CD160 antigenis a receptor on immune cells capable to deliver stimulatory or inhibitory signals that regulate cell activation and differentiation. Exists as a GPI-anchored and as a transmembrane form, each likely initiating distinct signaling pathways via phosphoinositol 3-kinase in activated NK cells and via LCK and CD247/CD3 zeta chain in activated T cells.
Synonyms :
CD160; BY55; BY55FLJ46513; NK1; NK28
References & Citations :
(1)Chabot S , Jabrane-Ferrat N , Bigot K , et al. A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor[J]. Journal of Experimental Medicine, 2011, 208(5):973-986.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
Osteopontin/OPN ProteinGene ID
FGL1 Proteinweb
Popular categories:
LOX-1
Signal Regulatory Protein gamma